Jefferies Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)

Jefferies analyst Research Report) yesterday and set a price target of $90.00. The company’s shares closed yesterday at $56.33.

According to TipRanks, Tsai is a 3-star analyst with an average return of 1.6% and a 47.37% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Xenon, and VistaGen Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intra-Cellular Therapies with a $71.63 average price target, implying a 27.16% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $75.00 price target.

See today’s best-performing stocks on TipRanks >>

ITCI market cap is currently $5.31B and has a P/E ratio of (15.55).

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer’s disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer’s disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

Read More on ITCI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More